The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future?
- 1 September 2007
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 115 (3) , 419-434
- https://doi.org/10.1016/j.pharmthera.2007.06.003
Abstract
No abstract availableKeywords
This publication has 115 references indexed in Scilit:
- Restoration of p53 function leads to tumour regression in vivoNature, 2007
- Gastric cancers in young and elderly patients show different genomic profilesThe Journal of Pathology, 2006
- A novel proteasome inhibitor NPI-0052 as an anticancer therapyBritish Journal of Cancer, 2006
- Age-Related Changes in Cochlear Gene Expression In Normal and Shaker 2 MiceJournal of the Association for Research in Otolaryngology, 2006
- ING2 PHD domain links histone H3 lysine 4 methylation to active gene repressionNature, 2006
- Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2Nature, 2006
- Genomic DNA methylation: the mark and its mediatorsPublished by Elsevier ,2006
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- The language of covalent histone modificationsNature, 2000